MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


AIM WINNERS & LOSERS: TruFin hails ‘strong’ trading; SkinBio falls

ALN

The following stocks are the leading risers and fallers on AIM on Thursday.

----------

AIM - WINNERS

----------

TruFin PLC, up 18% at 117.88 pence, 12-month range 42.00p-118.44p. TruFin predicts sharp half-year revenue growth amid ‘momentum’ at games publisher Playstack. The holding company of three growth-focused technology businesses operating in early payment provision, invoice finance and mobile games publishing, says revenue in the six months to June 30 rose 40% to £35.5 million from £25.3 million a year prior. ‘This strong performance has been primarily driven by continued momentum within Playstack,’ it adds. Adjusted earnings before interest, tax, depreciation and amortisation of £6.7 million are expected, more than doubling on-year from £2.9 million.

----------

OptiBiotix Health PLC, up 15% at 11.75p, 12-month range 10.00p-27.00p. The life sciences business says a product containing its Slimbiome appetite reducing offering has been launched. It has been launched in Hydroxycut, a weight loss supplement in the US. ‘This news is significant for the company as it represents the inclusion of SlimBiome in the products of one of the USA’s most popular weight management brands which has led to orders totalling just under five metric tonnes for SlimBiome in 2025. The board believes that the opportunity has potential for future development and will provide further updates in due course,’ it adds.

----------

AIM - LOSERS

----------

SkinBioTherapeutics PLC, down 7.3% at 14.25p, 12-month range 9.00p-27.50p. The life science firm focused on skin health expects to report weaker annual revenue than market forecasts, due to order timing. It expects revenue for the year to June 30 between £4.5 million and £4.8 million, jumping from £1.2 million a year prior. ‘Revenues were slightly lower than market expectations due to timing of orders for Dermatonics and BTS, much of which occurred just after the year end,’ it adds.

----------

Copyright 2025 Alliance News Ltd. All Rights Reserved.